过继免疫治疗在肝细胞性肝癌术后的应用  

The Application of Adoptive Immunotherapy in the Postoperative Hepatocellular Carcinoma

作　　者：钟鉴宏[1] 马良[1] 黎乐群[1] 

机构地区：[1]广西医科大学附属肿瘤医院肝胆外科,南宁530021

出　　处：《医学综述》2011年第4期527-529,共3页Medical Recapitulate

基　　金：国家自然科学基金(30960021)

摘　　要：早期诊断技术及手术技巧等的提高使得肝细胞性肝癌术后生存率显著提高,但是术后复发及转移仍威胁着患者的生命。肝细胞性肝癌术后辅助过继免疫治疗是众多辅助治疗中的一种,可明显降低肝癌根治性术后复发率,但对总生存率影响不大。肝细胞性肝癌术后开始过继免疫治疗的时间、使用剂量、治疗次数及间隔时间没有形成统一意见是其临床上应用不多的原因。The postoperative survival rate is improved markedly due to early diagnosis and great improvement of hepatic operation skill,but the postoperative relapse and metastasis are still threatening the life of the patients.Postoperative adjuvant adoptive immunotherapy,which has impact on reducing recurrence rate instead of overall survival rate,is one of the adjuvant treatments for patients with hepatocellular carcinoma postoperatively.No consensus about the time of treatment,dosage,rate of injection and time interval between treatments,has been made.These reasons restrict the usage of adoptive immunotherapy for patients with hepatocellular carcinoma postoperatively.

关 键 词：肝细胞性肝癌 根治性切除 过继免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤] R730.55[医药卫生—临床医学]